Navigation Links
Branded Prescription Pharmaceutical Sales Outlook to 2016
Date:3/19/2012

NEW YORK, March 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Branded Prescription Pharmaceutical Sales Outlook to 2016

http://www.reportlinker.com/p0799256/Branded-Prescription-Pharmaceutical-Sales-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

In 2011, the Branded PharmaVitae Universe achieved sales of $558bn having experienced a compound annual growth rate (CAGR) of 9.3% between 2003 and 2010, and a net sales growth of $253bn. However, during 2011–16 sales are forecast to grow by a CAGR of only 1.0%, with no growth forecast in 2012, and branded prescription sales rising by just $29bn by 2016.Analyzes the forecast sales of the Branded PharmaVitae Universe according to molecule typeAnalyzes the forecast sales of the Branded PharmaVitae Universe according to therapy areaAnalyzes the forecast sales of the Branded PharmaVitae Universe according to geographical marketAnalyzes the forecast sales of the Branded PharmaVitae Universe according to formulation type

By 2016 the small molecule market will contract by $5bn compared to 2011 sales as a direct consequence of the patent cliff and resultant generic erosion of branded sales. In preparation for this, the pharmaceutical industry has for some years been shifting its strategy to focus increasingly on high-growth markets such as biologics.

With US sales forecast to contract, pharmaceutical companies have turned to cost cutting and restructuring their US operations, while expanding in the high growth emerging markets. In fact, branded sales in the rest of world markets are forecast to represent 30.0% of sales in the Branded PharmaVitae Universe in 2016.

The pharmaceutical industry is shifting its R&D focus toward developing novel, high value, and often biologic therapies for the treatment of more niche indications. Reflecting this, infectious diseases and oncology are forecast to experience strong growth with additional sales of $10bn and $26bn by 2016, respectively.

Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2016Quantify the size and growth of the pharmaceutical marketAssess drivers and resistors of the prescription pharmaceutical market

EXECUTIVE SUMMARYStrategic scoping and focusKey findingsRelated reportsFORECAST PRESCRIPTION PHARMACEUTICAL SALES ANALYSISThe Branded PharmaVitae Universe will experience sales growth of only 1.0% per year out to 2016Newly launched and core drugs will collectively offset the sales loss from expiry productsThe pharmaceutical industry continues to expand in the biologic sector Injectable drugs are set to drive market growth The industry will derive the majority of its sales from externally sourced products by 2016The rest of world markets alone will offset the sales decline in the USSecondary care therapy areas are becoming a priority for pharmaSales of blockbuster drugs are expected to contract during 2011–16BIBLIOGRAPHYPublications and online articles Datamonitor reports and productsAPPENDIXThe Branded PharmaVitae Universe

TABLES

Table: Forecast prescription pharma sales ($bn) and year-on-year growth rate (%) for the Branded PharmaVitae Universe, 2011–16

Table: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16

Table: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16

Table: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16

Table: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011–16

Table: Forecast sales for the Branded PharmaVitae Universe ($m), 2011–16

FIGURES

Figure: Drivers and resistors for global sales growth of prescription products from the Branded PharmaVitae Universe, 2011–16Figure: Global prescription pharma sales ($bn) and year-on-year growth rate (%), 2003–16Figure: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2003–16Figure: Difference in global combined sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by launch/core/expiry/generic portfolio, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by molecule type, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by delivery mechanism, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by product source, 2011–16Figure: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2003–16Figure: Difference in combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by geography, 2011–16Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16Figure: Sales growth for the Branded PharmaVitae Universe, by therapy area, 2011–16Figure: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2003–16Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011 and 2016Figure: Sales growth for the Branded PharmaVitae Universe, by product value, 2011–16

Companies mentioned

GlaxoSmithKline Plc, Hutchison 3G UK Limited, Johnson & Johnson, Merck KGaA, Schindler Holding Ltd., Telstra Corporation Limited

To order this report:Pharmaceutical Industry: Branded Prescription Pharmaceutical Sales Outlook to 2016

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
2. Lupin Expands Branded Play
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
5. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
6. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
7. Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies
8. GNC Teams With Sakar International for Branded Health and Wellness Product Line
9. Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients
10. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
11. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):